ESI-09
| CAS No. | 263707-16-0 | Cat. No. | BCP10854 |
| Name | ESI-09 | ||
| Synonyms | ESI09;ESI 09; | ||
| Formula | C16H15ClN4O2 | M. Wt | 330.77 |
| Description | ESI-09 inhibited cAMP-mediated EPAC2 GEF activity with an apparent IC50 of 1.4± 0.1 uM. Similarly, ESI-09 was also effective in suppressing cAMP-mediated EPAC1 GEF activity with an apparent IC50 of 3.2± 0.4 uM. ESI-09 is capable of blocking EPAC-mediated Akt activation, the phosphorylation status of T308 and S473 of Akt in the pancreatic cancer cell line AsPC-1, which overexpresses EPAC1, was followed using antiphospho-Akt antibodies. when the pancreatic cancer cell lines AsPC-1 and PANC-1 were pretreated with ESI-09, a significant decrease in cell migration was observed using both Transwell migration/invasion and wound healing assays. | ||
| Pathways | Others Pathway | ||
| Targets | Others | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.